Machine Learning

A new partnership arms independent cancer clinics with advanced AI and data analytics, aiming to improve patient care and ensure their survival.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

ITRS's acquisition of French DEM leader IP-Label signals a major move to challenge market giants by creating a holistic observability platform for Europe.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

A new study on oral testosterone therapy for men 65-80 could reshape geriatric care, challenge FDA guidelines, and unlock a multi-billion dollar market.

The firm is now recruiting for a Phase 1 trial of HWK-007 and has submitted an IND for HWK-016, targeting tough lung, ovarian, and endometrial cancers.

While humanoid robots grab headlines, Linkerbot quietly captured 80% of the dexterous hand market with revolutionary cost and production scale.

The deal integrates specialized AI and therapist-led platforms to boost mental health access for remote communities and spearhead global expansion.

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

With multiple clinical trials advancing and a savvy global expansion, RESTEM is poised to challenge the treatment paradigm for autoimmune disorders.

Safi Biotherapeutics and ARMI | BioFabUSA achieve a critical step toward mass-producing red blood cells, offering hope for patients and military readiness.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.

A new partnership leverages in vivo screening to find novel obesity targets, aiming to revolutionize a market projected to exceed $100 billion.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

858 Therapeutics' novel PARG inhibitor offers new hope for patients with a deadly, drug-resistant form of ovarian cancer, accelerating its path to approval.

Accenture's new investment in Profitmind's agentic AI platform signals a major shift for retail, promising to automate complex decisions and bridge the gap between data and action.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

Keystone doubles down on AI advisory with Audax Private Equity's backing, spinning off its supply chain software unit into a new powerhouse, Keystone AI.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.